Device Trial Radar · NCT07843004
Capitalizing on AI to CapTure Undiagnosed Structural Heart Disease
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
4,000
Planned (sponsor's estimate)
Start
Sep 16, 2026
Primary completion
Jun 1, 2027
Study completion Jun 1, 2028
Sponsor
- Lead sponsor
- Pierre EliasAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Edwards Lifesciences; National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Sep 25, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Screening
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Doctors are testing a new tool called EchoNext to see if it can help find heart problems earlier. EchoNext looks at the heart's electrical test, called an ECG, and uses artificial intelligence (AI) to check for signs of structural heart disease (SHD). SHD includes conditions like weak heart pumping, heart valve problems, or extra thickening of the heart muscle. These problems are common but often go undiagnosed until they cause serious issues like heart failure or stroke. The main questions this study will answer are: Can EchoNext alerts help emergency doctors find hidden heart problems sooner? Does this lead to more follow-up heart tests, like an echocardiogram (heart ultrasound)? What this means for patients: If a person has an ECG in the Emergency Department, the EchoNext tool may be used to check their heart. If the tool finds something unusual, their doctor may receive an alert and may then recommend further heart tests or follow-up care. This study will help researchers learn if using EchoNext improves early diagnosis and treatment of heart disease.
Conditions
- Structural Heart Abnormality
- Valve Heart Disease
- Heart Diseases
- Cardiovascular Diseases
Interventions
EHR AlertDevice
EKG Algorithm to identify structural heart disease
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of new diagnoses of Structural Heart Disease (SHD)Time frame: 180 days post index ED visit
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Columbia University Irving Medical Center / NewYork-Presbyterian
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.